Neuralink is making remarkable progress in restoring the ability to communicate for people with severe speech impairments. Through its ongoing VOICE clinical trial, the company is demonstrating how brain implants can decode intended speech from neural signals and convert them into clear, synthesized voice output or text—offering new hope to patients with conditions like ALS.
A Life-Changing Milestone for Patients
In January 2026, Kenneth (Ken) Shock became the second participant in Neuralink’s VOICE study. Diagnosed with ALS in 2024, Ken had lost much of his natural speech ability. With the Neuralink N1 implant, he can now express himself simply by thinking. The system translates his brain activity into spoken words using a synthesized voice cloned from his own pre-ALS recordings—often referred to affectionately as “OG Ken.”
In video demonstrations, Ken clearly “says” phrases such as “I’m talking to you with my mind” without moving his mouth. His wife and family have described the emotional impact of hearing his voice again after years of progressive loss. Earlier participant Brad Smith, who joined in 2025, has similarly used the technology for video narration and computer control using only his thoughts.
How the Technology Works
The N1 implant features ultra-thin threads with electrodes that are placed in brain regions responsible for speech production, particularly areas near the motor cortex that control movements of the mouth, tongue, and larynx. These electrodes capture high-bandwidth neural activity in real time.
Advanced AI and machine learning models then decode these signals—mapping patterns of brain activity to intended phonemes, words, or full sentences. The decoded output is sent to a speech synthesizer, producing natural-sounding audio or on-screen text. Patients can either imagine speaking, silently mouth words, or simply intend the words, and the system converts the thought into communication.
Current speeds are improving rapidly, with the long-term goal of reaching conversational rates of around 140 words per minute. This represents a significant leap from earlier Neuralink demonstrations focused primarily on cursor control through imagined hand movements.
The VOICE Clinical Trial
The VOICE study (ClinicalTrials.gov identifier NCT07224256) specifically targets the restoration of speech for individuals with ALS, stroke, or other neurological conditions that impair verbal communication. As of early 2026, multiple participants—part of Neuralink’s growing group of over 21 “Neuralnauts” across various trials—are involved. The trial emphasizes safety, reliability, and iterative improvements, including higher electrode counts and refined surgical techniques.
The technology remains investigational and is not yet available for general use. Neuralink continues to recruit eligible participants through its Patient Registry while refining the system based on real-world feedback.
Looking Ahead
Neuralink’s thought-to-speech system builds on foundational work in brain-computer interfaces and could eventually extend far beyond medical applications. For now, its greatest impact is deeply personal: restoring autonomy, reducing isolation, and reconnecting individuals with their loved ones.
Ken Shock’s journey, captured in Neuralink’s official demonstration videos, stands as a powerful example of what this technology can achieve. As the VOICE trial advances, it brings us closer to a future where the barrier between thought and expression can be bridged for millions affected by speech-limiting conditions.
About The Author
